SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Jules who wrote (1915)2/23/1999 2:35:00 PM
From: Steve Harmon  Read Replies (1) | Respond to of 2742
 
The extra cash from Techne puts CISTRON's total cash at 58 cent a share. Companies are paying 20-30% premium for cash. Cistron should get an absolute minimum of 80 cent a share when they sell for JUST their cash.

That gives the buyer the $30 million PMC deal for FREE.

Of course in the past whenever CIST gets more cash their stock price goes lower. Shareholders are DE-hanced!



To: Jules who wrote (1915)2/23/1999 4:40:00 PM
From: Rudy Saucillo  Read Replies (4) | Respond to of 2742
 
Nice deal for Techne. As I've said on this thread several times, I'm very impressed with the company.

BTW, CIST's business strategy and potential partner weren't hard to figure out.

See posts 1668 and 1692 for some early speculation.

Rudy



To: Jules who wrote (1915)6/1/1999 2:07:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
emedtrade.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News